Document is current
Any future updates will be listed below
-
Authors
Jaiswal, Swati
Nyquist, Sarah K.
Boyce, Shayla
Jivanjee, Tasneem
Ibrahim, Samira
Bromley, Joshua D.
Gatter, G. James
Gideon, Hannah
Patel, Kush
Ganchua, Sharie Keanne
Berger, Bonnie
Fortune, Sarah M.
Flynn, JoAnne L.
Shalek, Alex K.
Behar, Samuel M.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases
National Institutes of Health (R01 AI114674)
U.S. Department of Health and Human Services (75N93019C00071)
The Bill and Melinda Gates Foundation
- License Information
-
More Information
Article History
Received: 22 April 2022
Accepted: 1 September 2022
First Online: 12 September 2022
Declarations
:
: Chinese cynomolgus macaques were purchased from Valley Biosystems (West Sacramento, CA). All experimental manipulations, protocols, and care of the animals were approved by the University of Pittsburgh School of Medicine Institutional Animal Care and Use Committee (IACUC). The protocol assurance number for our IACUC is D16-00118. Our specific protocol approval numbers for this project are 18124275 and IM-18124275–1. The IACUC adheres to national guidelines established in the Animal Welfare Act (7 U.S.C. Sections 2131—2159) and the Guide for the Care and Use of Laboratory Animals (8th Edition) as mandated by the U.S. Public Health Service Policy. Sedated animals were humanely euthanatized using sodium pentobarbital and phenytoin. All methods are reported in accordance with ARRIVE guidelines (for complete details about the animals used in this study, see Gideon, Hughes, Tzounas, et al. [].
: Not applicable.
: A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ochre Bio, Third Rock Ventures, Hovione, Relation Therapeutics, FL82, and Dahlia Biosciences. All other authors report no conflict of interest.
